Better diabetic retinopathy outcomes seen with monthly ranibizumab

09/6/2013 | Medscape (free registration)

Data on diabetic retinopathy patients showed those who received monthly ranibizumab treatment were more likely than those who received sham injections to attain improvements in vision and disease severity at three years. Researchers also found patients in the ranibizumab arm were three times less likely to develop proliferative diabetic retinopathy than those in the control group. The findings were presented at the American Society of Retina Specialists meeting.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC